Vikram Lamba
Nessuna posizione attualmente
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Han Lee | M | - |
Immpact Bio USA, Inc.
Immpact Bio USA, Inc. BiotechnologyHealth Technology ImmPACT Bio USA, Inc. operates as a cell therapy company. The firm develops potent and selective engineered T-cells for the treatment of solid tumors. The company is headquartered in Camarillo, CA. | 1 anni |
Biren Amin | M | 51 |
Immpact Bio USA, Inc.
Immpact Bio USA, Inc. BiotechnologyHealth Technology ImmPACT Bio USA, Inc. operates as a cell therapy company. The firm develops potent and selective engineered T-cells for the treatment of solid tumors. The company is headquartered in Camarillo, CA. | 1 anni |
Paul Achleitner | M | 67 | 22 anni | |
Mahmoud Ameri | M | - | 9 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Konstantinos Alataris | M | - | 2 anni | |
Elka Yaron | F | - | 2 anni | |
Marc R. Schneebaum | M | 69 |
Predictive Biosciences, Inc.
Predictive Biosciences, Inc. Medical/Nursing ServicesHealth Services Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates. | 2 anni |
Kleanthis Xanthopoulos | M | 66 | 8 anni | |
Bruce Steel | M | 57 | 5 anni | |
Ulrich Hauck | M | 60 | 12 anni | |
Karl-Ludwig Kley | M | 72 | 16 anni | |
Joseph Hagan | M | 55 | 7 anni | |
Troy Wilson | M | 55 | 5 anni | |
Johannes M. Dietsch | M | 62 | 16 anni | |
Aaron Shnitzer | M | - | - | |
Eric Scharin | M | - | - | |
Wing-Kei Tso | F | 63 | 2 anni | |
Bernd Metzner | M | 53 | 4 anni | |
Frank Morich | M | 69 | 20 anni | |
Hayley Lewis | F | 48 | 6 anni | |
Holger Zimmermann | M | - | 6 anni | |
Paul Grant Higham | M | - | 11 anni | |
Wolfgang Plischke | M | 72 | 19 anni | |
David Roblin | M | 57 | 2 anni | |
Thomas Ross | M | 63 |
Predictive Biosciences, Inc.
Predictive Biosciences, Inc. Medical/Nursing ServicesHealth Services Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates. | 2 anni |
Nandan Oza | M | 61 | 2 anni | |
Joachim Bender | M | 69 | 15 anni | |
Neil Gibson | M | 67 | 4 anni | |
Lars Benecke | M | - | - | |
Manuela Strauch | F | 52 | - | |
William Carson | M | 76 | 8 anni | |
Duane Tucker | M | - | 2 anni | |
Anja Dubbert | F | 45 | 1 anni | |
Richard M. Mitrano | M | 73 |
Predictive Biosciences, Inc.
Predictive Biosciences, Inc. Medical/Nursing ServicesHealth Services Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates. | 2 anni |
Rolf Hoffmann | M | 48 | - | |
Rick Ryan | M | - | 14 anni | |
Thomas Hoffmann | M | 53 | - | |
Thomas Henkel | M | 62 | - | |
Dariusz Adam Bak | M | 55 | 4 anni | |
Peter Vanacker | M | 58 | 4 anni | |
Hans-Peter Schaefer | M | 73 | 14 anni | |
Stefan Hesse | M | - | - | |
Katharina Jansen | M | - | 22 anni | |
Wilhelm Stahl | M | 64 | - | |
Bernard Mathias Becker | M | 58 | 2 anni | |
Heino von Prondzynski | M | 73 | 20 anni | |
Rainier van Roessel | M | 66 | 11 anni | |
Albert P. L. Stroucken | M | 76 | 1 anni | |
Alexander Rosar | M | - | - | |
Knut Kleedehn | M | 86 | - | |
Donald J. Kellerman | M | 68 | 7 anni | |
Christopher Krueger | M | 56 | 1 anni | |
Charles W. Wolcott | M | 71 | 7 anni | |
Lodewijk Christian van Wachem | M | 92 | - | |
Bernhard Opitz | M | 66 | 20 anni | |
Ernst-Ludwig Winnacker | M | 82 | 19 anni | |
Stephen W. Zaruby | M | 61 | 6 anni | |
Paolo Pucci | M | 63 | 7 anni | |
Frank Armstrong | M | 67 | 3 anni | |
Thorsten von Stein | M | 62 | - | |
David A. Lowe | M | 77 | 5 anni | |
Caren Mason | F | 70 | 7 anni | |
David Ebsworth | M | 69 | 19 anni | |
Pol Bamelis | M | 85 | 36 anni | |
Peter E. Daddona | M | 79 | 1 anni | |
Terry Conrad | M | - | 3 anni | |
Joe W. Martin | M | 71 | 12 anni | |
Michael Barrett | M | 81 | 1 anni | |
Colin Foster | M | 61 | 10 anni | |
Kevin B. Bacon | M | 59 | 5 anni | |
Mara Aspinall | F | 61 |
Predictive Biosciences, Inc.
Predictive Biosciences, Inc. Medical/Nursing ServicesHealth Services Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates. | 2 anni |
Douglas Liu | M | 62 | 9 anni | |
David M. Hillenbrand | M | 76 | - | |
Jürgen Weber | M | 82 | - | |
Hans-Olaf Henkel | M | 84 | 10 anni | |
Laxmi Peri | M | 65 | 1 anni | |
Suseelan R. Pookote | M | 70 | 19 anni | |
Walter Wenninger | M | 86 | 6 anni | |
John P. Richard | M | 66 | 1 anni | |
Hoa Hong | F | - | 4 anni | |
Anat Nursella | F | - |
Immpact Bio USA, Inc.
Immpact Bio USA, Inc. BiotechnologyHealth Technology ImmPACT Bio USA, Inc. operates as a cell therapy company. The firm develops potent and selective engineered T-cells for the treatment of solid tumors. The company is headquartered in Camarillo, CA. | 2 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Germania | 55 | 67.90% |
Stati Uniti | 20 | 24.69% |
Hong Kong | 9 | 11.11% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Vikram Lamba
- Contatti personali